Enjoy your
FREE PREVIEW which shows only 2022 data and 25 documents. Contact
Patent Forecast for full access.
AI Biotech/Diagnostics: Other Innovation
Search All Applications in AI Biotech/Diagnostics: Other Innovation
Application US20170191129
Published 2017-07-06
Biomarker Signature Method, And Apparatus And Kits Thereof
The present invention discloses methods, kits, and apparatus as well as reagents and compositions associated therewith for deriving an indicator for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. Also disclosed is a biomarker signature for use in diagnosing the presence, absence or degree of at least one condition in a biological subject or in prognosing at least one condition in a biological subject. The present invention further discloses methods, kits and apparatus, as well as reagents and compositions associated therewith, for identifying biomarkers for use in a biomarker signature.
Much More than Average Length Specification
View the Patent Matrix® Diagram to Explore the Claim Relationships
USPTO Full Text Publication >
- 1-142. (canceled)
- 143. A method for inhibiting the development or progression of inSIRS or ipSIRS in a subject, the method comprising: (1) providing an indicator used in assessing a likelihood of the presence of inSIRS or ipSIRS in the subject; and (2) exposing the subject to a treatment regimen for treating inSIRS based on the indicator indicating a likely presence of inSIRS in the subject, or exposing the subject to a treatment regimen for treating ipSIRS based on the indicator indicating a likely presence of ipSIRS in the subject, wherein the indicator is determined by an indicator-determining method, the indicator-determining method comprising: (a) determining at least one pair of biomarker values, each biomarker value being a value measured or derived for a corresponding immune system biomarker in a sample taken from the subject; (b) determining at least one derived biomarker value using the at least one pair of biomarker values, the derived biomarker value being indicative of a ratio of concentrations of a corresponding pair of immune system biomarkers in the sample; and (c) determining the indicator based on the at least one derived biomarker value,
wherein the at least one pair of biomarker values comprises a first pair of biomarker values comprising first and second biomarker values corresponding to first and second immune system biomarkers, respectively, wherein the first immune system biomarker represents a polynucleotide expression product of the PLA2G7 gene and wherein the second immune system biomarker represents a polynucleotide expression product of the PLAC8 gene.
- 149. A method for inhibiting the development or progression of inSIRS or ipSIRS in a subject, the method comprising: (1) providing an indicator used in assessing a likelihood of the presence of inSIRS or ipSIRS in the subject; and (2) exposing the subject to a treatment regimen for treating inSIRS based on the indicator indicating a likely presence of inSIRS in the subject, or exposing the subject to a treatment regimen for treating ipSIRS based on the indicator indicating a likely presence of ipSIRS in the subject, wherein the indicator is determined by an indicator-determining method, the indicator-determining method comprising: (a) determining at least two pairs of biomarker values comprising a first pair of biomarker values and a second pair of biomarker values, each biomarker value being a value measured or derived for a corresponding immune system biomarker in a sample taken from the subject; (b) determining a first derived biomarker value using the first pair of biomarker values, the first derived biomarker value being indicative of a ratio of concentrations of a corresponding first pair of immune system biomarkers in the sample; (c) determining a second derived biomarker value using the second pair of biomarker values, the second derived biomarker value being indicative of a ratio of concentrations of a corresponding second pair of immune system biomarkers in the sample; and (d) determining the indicator based on a combination of at least the first derived biomarker value and the second derived biomarker value,
wherein one of the first pair of immune system biomarkers represents a polynucleotide expression product of the PLA2G7 gene and wherein the other of first pair of immune system biomarkers represents a polynucleotide expression product of the PLAC8 gene, and wherein one of the second pair of immune system biomarkers represents a polynucleotide expression product of the CEACAM4 gene and wherein the other of the second pair of immune system biomarkers represents a polynucleotide expression product of the LAMP1 gene.
